three treatment arms stratified by MMR status (proficient v deficient), disease status (newly diagnosed v recurrent), and geographic region (Asia v non-Asia)
may 2023 press release : PUBLISHED26 May 2023DUO-E is the first global Phase III trial of immunotherapy plus PARP inhibition to demonstrate clinical benefit in this settingPositive high-level results from the DUO-E Phase III trial showed IMFINZI® (durvalumab) in combination with platinum-based chemotherapy followed by either IMFINZI plus LYNPARZA® (olaparib) or IMFINZI alone as maintenance therapy both demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to standard-of-care chemotherapy alone in patients with newly diagnosed advanced or recurrent endometrial cancer. There was a greater clinical benefit observed with the combination of IMFINZI and LYNPARZA as maintenance treatment.
DUO-E (durvalumab then durvalumab alone vs control arms), 2023 NCT04269200
durvalumab plus SoC (n=238) vs. placebo plus SoC (n=239)
randomized controlled trial
durvalumab
carboplatin/paclitaxel plus durvalumab followed by maintenance durvalumab plus placebo
placebo
carboplatin/paclitaxel plus placebo followed by placebo maintenance (control arm)
three treatment arms stratified by MMR status (proficient v deficient), disease status (newly diagnosed v recurrent), and geographic region (Asia v non-Asia)
may 2023 press release : PUBLISHED26 May 2023DUO-E is the first global Phase III trial of immunotherapy plus PARP inhibition to demonstrate clinical benefit in this settingPositive high-level results from the DUO-E Phase III trial showed IMFINZI® (durvalumab) in combination with platinum-based chemotherapy followed by either IMFINZI plus LYNPARZA® (olaparib) or IMFINZI alone as maintenance therapy both demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to standard-of-care chemotherapy alone in patients with newly diagnosed advanced or recurrent endometrial cancer. There was a greater clinical benefit observed with the combination of IMFINZI and LYNPARZA as maintenance treatment.